Why Are Aldeyra Therapeutics Shares Plummeting Today
Portfolio Pulse from Vandana Singh
Aldeyra Therapeutics received a Complete Response Letter from the FDA for the NDA of ADX-2191 due to lack of substantial evidence of effectiveness. The company plans to discuss ADX-2191 for PVRL with the FDA and explore an Expanded Access Program protocol. ALDX shares are down 24.80%.
June 21, 2023 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aldeyra Therapeutics' stock price dropped 24.80% after the FDA raised concerns about the effectiveness of ADX-2191 for PVRL.
The FDA's Complete Response Letter questioning the effectiveness of Aldeyra Therapeutics' ADX-2191 for primary vitreoretinal lymphoma (PVRL) has led to a significant drop in the company's stock price. The lack of substantial evidence of effectiveness in the NDA submission has negatively impacted investor sentiment, causing the stock price to plummet by 24.80%.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100